How would you manage a patient with DLBCL that progressed on/after EPOCH and subsequently treated with a CD19 allo CAR-T product within 90 days of receiving apheresis?

I'm sorry, but the question is unclear. Did his disease progress after CD19 allo CAR-T? If so, I would offer commercially FDA-approved CD19 CAR-T. The fact that his disease progressed quickly after allo CAR-T is possibly due to a lack of expansion and long-term persistence, which can be mitigated by...